Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001682852-26-000060
Filing Date
2026-05-01
Accepted
2026-05-01 16:10:14
Documents
89
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrna-20260331.htm   iXBRL 10-Q 1195425
2 EX-10.1 exhibit10133126.htm EX-10.1 197741
3 EX-31.1 exhibit31133126.htm EX-31.1 9042
4 EX-31.2 exhibit31233126.htm EX-31.2 8982
5 EX-32.1 exhibit32133126.htm EX-32.1 8107
11 mrna-20260331_g1.jpg GRAPHIC 63925
12 mrna-20260331_g2.jpg GRAPHIC 165976
  Complete submission text file 0001682852-26-000060.txt   8866127

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrna-20260331.xsd EX-101.SCH 56034
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrna-20260331_cal.xml EX-101.CAL 111629
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrna-20260331_def.xml EX-101.DEF 212266
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrna-20260331_lab.xml EX-101.LAB 679908
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrna-20260331_pre.xml EX-101.PRE 474862
93 EXTRACTED XBRL INSTANCE DOCUMENT mrna-20260331_htm.xml XML 1383028
Mailing Address 325 BINNEY STREET CAMBRIDGE MA 02142
Business Address 325 BINNEY STREET CAMBRIDGE MA 02142 6177146500
Moderna, Inc. (Filer) CIK: 0001682852 (see all company filings)

EIN.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38753 | Film No.: 26932593
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)